Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Patent
1993-11-22
1997-08-19
Jacobson, Dian C.
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
435208, A61K 3846, A61K 3847, C12N 940, C12N 1554
Patent
active
056585675
ABSTRACT:
Fabry disease results from an X-linked deficiency in the enzyme .alpha.-galactosidase A. The present invention is directed to recombinant human .alpha.-galactosidase A and provides baculovirus expression vectors and recombinant virus that provide stable expression of extracellular and intracellular levels of this enzyme in an insect cell culture. The recombinant-derived enzyme can be used in enzyme replacement therapy to treat Fabry patients. Composition useful in therapeutic administration of .alpha.-galactosidase A are also provided.
REFERENCES:
Bishop et al. (1981) "Affinity Purification of .alpha.-Galactosidase A from Human Spleen, Placenta, and Plasma with Elimination of Pyrogen Contamination":, The Journal of Biological Chemistry 256: 1307-1316.
Bishop et al. (1986) "Human .alpha.-Galactosidase A: Nucleotide Sequence of a cDNA Clone Encoding the Mature Enzyme", Proc. Natl. Acad. Sci. USA 83:4859-4863.
Calhoun et al. (1985) "Fabry Disease: Isolation of a cDNA Clone Encoding Human .alpha.-Galactosidase", Proc. Natl. Acad. Sci. USA 82:7364-7368.
Hantzopoulos et al. (1987) "Expression of the Human .alpha.-Galactosidase A in Escherichia coli K-12", Gene 57:159-169.
Luckow et al. (1988) "Trends in the Development of Baculovirus Expression Vectors" Biotechnology 6:47-55.
Quinn et al. (1987) "A Genomic Clone Containing the Promoter for the Gene Encoding the Human Lysosomal Enzyme, .alpha. Galactosidase A" Gene 58:177-188.
Smith et al. (1983) "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector" Molecular and Cellular Biology 3:2156-2165.
Tsuji et al. (1987) "Signal Sequence and DNA-Mediated Expression of Human Lysosomal .alpha.-Galactosidase A" Eur. J. Biochem. 165:275-280.
Calhoun David Hudgins
Coppola George
Jacobson Dian C.
Research Corporation Technologies Inc.
LandOfFree
Recombinant .alpha.-galactosidase A therapy for Fabry disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Recombinant .alpha.-galactosidase A therapy for Fabry disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant .alpha.-galactosidase A therapy for Fabry disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1102749